Sabrina A. Assoumou, MD MPH, is Assistant Professor of Medicine at Boston University School of Medicine and an attending physician in the section of Infectious Diseases at Boston Medical Center. She is a clinician-investigator who cares for human immunodeficiency virus (HIV)-infected patients at the BUSM/BMC’s Centers for Infectious Diseases. Her research focuses on medical complications of substance use including HIV and Hepatitis C virus (HCV). She is also interested in models of care and on improving the continuum of care for individuals with HIV and/or HCV. She is currently the Principal Investigator on an NIH K23 Mentored Career Development Award to improve linkage to care after testing for HIV and HCV at a drug detoxification center.
Dr. Assoumou has published in multiple journals including Clinical Infectious Diseases, AIDS, Annals of Internal Medicine and the Journal of American Medical Association. Her work has also been included in the American Association for the Study of Liver Diseases (AASLD)/ Infectious Diseases Society of America (IDSA) recommendations for testing, managing and treating HCV (Assoumou et al., Clin Infect Dis 2018) as well as HCV testing recommendations by the Centers for Disease Control and Prevention (Assoumou et al., Clin Infect Dis 2018 and Assoumou et al., Clin Infect Dis. 2019). Dr. Assoumou has also presented her findings at the National Academy of Sciences to the panel tasked with developing a National Strategy for the Elimination of Hepatitis B and C and at international scientific meetings such as IDWeek and the Conference on Retroviruses and Opportunistic Infections (CROI).
Dr. Assoumou graduated magna cum laude from Williams College and obtained her medical degree from the University of Rochester School of Medicine and Dentistry. She then completed a combined Internal Medicine/Pediatrics residency at Brown University and an Infectious Diseases Fellowship at Harvard University’s Beth Israel Deaconess Medical Center where she was awarded the Finland Award for Research Excellence. She also earned a Masters of Public Health at the Harvard T.H. Chan School of Public Health. Dr. Assoumou received an Excellence in Teaching Hospital-Based Faculty Award at BMC in 2017. She was also recognized as the Distinguished Faculty of the Month in April 2020 for her service to the BUSM community in teaching, service on committees, mentoring of students, trainees and junior faculty. The same year she also received a Department of Medicine Evans Junior Faculty Research Merit Award recognizing an outstanding record of scholarship and research.
- University of Rochester School of Medicine & Dentistry, MD
- Harvard School of Public Health, MPH
- Williams College, BA
- Published on 5/21/2021
Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 08 01; 225:108764. PMID: 34051547.
- Published on 4/27/2021
Burns RH, Pierre CM, Marathe JG, Ruiz-Mercado G, Taylor JL, Kimmel SD, Johnson SL, Fukuda HD, Assoumou SA. Partnering With State Health Departments to Address Injection-Related Infections During the Opioid Epidemic: Experience at a Safety Net Hospital. Open Forum Infect Dis. 2021 Aug; 8(8):ofab208. PMID: 34409120.
- Published on 3/30/2021
Berger Z, Altiery DE Jesus V, Assoumou SA, Greenhalgh T. Long COVID and Health Inequities: The Role of Primary Care. Milbank Q. 2021 06; 99(2):519-541. PMID: 33783907.
- Published on 3/22/2021
Assoumou SA, Paniagua SM, Gonzalez P, Wang J, Beckwith CG, White LF, Taylor JL, Coogan K, Samet JH, Linas BP. HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges. AIDS Behav. 2021 Aug; 25(8):2591-2598. PMID: 33751315.
- Published on 2/24/2021
Sinha P, Jafarzadeh SR, Assoumou SA, Bielick CG, Carpenter B, Garg S, Harleen S, Neogi T, Nishio MJ, Sagar M, Sharp V, Kissin EY. The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study. J Infect Dis. 2021 02 24; 223(4):581-588. PMID: 33216906.
- Published on 2/1/2021
Linas BP, Savinkina A, Madushani RWMA, Wang J, Eftekhari Yazdi G, Chatterjee A, Walley AY, Morgan JR, Epstein RL, Assoumou SA, Murphy SM, Schackman BR, Chrysanthopoulou SA, White LF, Barocas JA. Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Netw Open. 2021 02 01; 4(2):e2037259. PMID: 33587136.
- Published on 1/11/2021
Assoumou SA, Sian CR, Gebel CM, Linas BP, Samet JH, Bernstein JA. Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A qualitative study. Drug Alcohol Depend. 2021 03 01; 220:108526. PMID: 33465604.
- Published on 9/2/2020
Assoumou SA, Paniagua SM, Linas BP, Wang J, Samet JH, Hall J, White LF, Beckwith CG. Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial. J Infect Dis. 2020 09 02; 222(Suppl 5):S376-S383. PMID: 32877557.
- Published on 7/25/2020
Sinha P, Mostaghim A, Bielick CG, McLaughlin A, Hamer DH, Wetzler LM, Bhadelia N, Fagan MA, Linas BP, Assoumou SA, Ieong MH, Lin NH, Cooper ER, Brade KD, White LF, Barlam TF, Sagar M. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. Int J Infect Dis. 2020 Oct; 99:28-33. PMID: 32721528.
- Published on 6/27/2020
Assoumou SA, Nolen S, Hagan L, Wang J, Eftekhari Yazdi G, Thompson WW, Mayer KH, Puro J, Zhu L, Salomon JA, Linas BP. Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. Am J Med. 2020 11; 133(11):e641-e658. PMID: 32603791.
View 16 more publications: View full profile at BUMC